Tyrphostin AG1478 supresses proliferation and invasion of human breast cancer cells

International Journal of Oncology

Volumn 33, Issue 3, 2008, Pages 595-602

  Zhang, Yun Gang ^a,b   Du, Qiang ^a   Fang, Wei Gang ^a   Jin, Mu Lan ^b   Tian, Xin Xia ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Epidermal growth factor receptor; Tyrphostin AG1478

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GELATINASE B; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; TYRPHOSTIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ASSAY; CELL CLONE; CELL COUNT; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLUORESCENCE ACTIVATED CELL SORTING; GROWTH INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; WESTERN BLOTTING; BIOSYNTHESIS; BREAST TUMOR; CELL MOTION; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; MATRIX METALLOPROTEINASE 9; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TELOMERASE; TYRPHOSTINS;

EID: 54849186000     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000045     Document Type: Article

References (41)

1. Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M and Holcmann M: The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 75: 770-787, 2007.
2. Press MF and Lenz HJ: EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 67: 2045-2075, 2007.
3. Laskin JJ and Sandler AB: Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 30: 1-17, 2004.
4. Marshall J: Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107: 1207-1218, 2006.
5. Pander J, Gelderblom H and Guchelaar HJ: Pharmacogenetics of EGFR and VEGF inhibition. Drug Discov Today 12: 1054-1060, 2007.
6. Harari PM, Allen GW and Bonner JA: Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 25: 4057-4065, 2007.
7. Harari PM: Anti-EGFR therapy update: clinical experience and adverse event insights. Oncology (Williston Park) 20 (Suppl. 2): 3-4, 2006.
8. Rocha-Lima CM, Soares HP, Raez LE and Singal R: EGFR targeting of solid tumors. Cancer Control 14: 295-304, 2007.
9. Kurokawa H and Arteaga CL: Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 7 (Suppl. 12): S4436-S4442, 2001.
10. Hynes NE and Lane HA: ErbB receptors and cancer: the complexity of targeted inhibitors. Nature Rev Cancer 5: 341-354, 2005.
11. Baselga J, Albanell J, Ruiz A, et al: Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23: 5323-5333, 2005.
12. von Minckwitz G, Jonat W, Fasching P, et al: A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 89: 165-172, 2005.
13. Emlet DR, Schwartz R, Brown KA, Pollice AA, Smith CA and Shackney SE: HER2 expression as a potential marker for response to therapy targeted to the EGFR. Br J Cancer 94: 1144-1153, 2006.
14. Lichtner RB, Menrad A, Sommer A, Klar U and Schneider MR: Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 61: 5790-5795, 2001.
15. Zhu XF, Liu ZC, Xie BF, et al: EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett 169: 27-32, 2001.
16. Busse D, Doughty RS, Ramsey TT, et al: Reversible G1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27KIP1 independent of MAPK activity. J Biol Chem 275: 6987-6995, 2000.
17. Nagane N, Levitzki A, Gazit A, Cavanee WK and Huang HJ: Drug resistance of human glioblastoma cells conferred by a tumour specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase 3-like proteases. Proc Natl Acad Sci USA 95: 5724-5729, 1998.
18. Lei W, Mayotte EJ and Levitt LM: Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells. Anticancer Res 19: 221-228, 1999.
19. Johns TG, Luwor RB, Murone C, et al: Antitumour efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 100: 15871-15876, 2003.
20. He HY, Fang WG, Zheng J, et al: Mechanisms of mitogenactivated protein kinase phosphatase-5 regulation growth and invasion of a human prostate cancer cell line. Natl Med J China 83: 1812-1818, 2003.
21. Ogretmen B, McCauley MD and Safa AR: Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance. Biochemistry 37: 11679-11691, 1998.
22. Papageorgio C and Perry MC: Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Cancer Invest 25: 647-657, 2007.
23. Ellis AG, Doherty MM, Walker F, et al: Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochemical Pharmacol 71: 1422-1434, 2006.
24. Shushan A, Rojansky N, Laufer N, et al: The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth. Hum Reprod 19: 1957-1967, 2004.
25. Partik G, Hochegger K, Schörkhuber M and Marian B: Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumour cells in vitro. J Cancer Res Clin Oncol 125: 379-388, 1999.
26. Perera RM, Narita Y, Furnari FB, et al: Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 11: 6390-6399, 2005.
27. Nakamura H, Takamori S, Fujii T, et al: Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer. Cancer Lett 230: 33-46, 2005.
28. Zhou Y and Brattain MG: Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis. Cancer Res 65: 5848-5856, 2005.
29. Kari C, Chan TO, Rocha de Quadros M and Rodeck U: Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 63: 1-5, 2003.
30. Budiyanto A, Bito T, Kunisada M, Ashida M, Ichihashi M and Ueda M: Inhibition of the epidermal growth factor receptor suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma cells. J Invest Dermatol 121: 1088-1094, 2003.
31. Tian XX, Pang JC, Zheng J, et al: Antisense epidermal growth factor receptor RNA transfection in human glioblastoma cells down-regulates telomerase activity and telomere length. Br J Cancer 86: 1328-1332, 2002.
32. Maida Y, Kyo S, Kanaya T, et al: Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene 21: 4071-4079, 2002.
33. Smith LL, Coller HA and Roberts JM: Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 5: 474-479, 2003.
34. Tan X, Egami H, Abe M, Nozawa F, Hirota M and Ogawa M: Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway. J Clin Pathol 58: 1242-1248, 2005.
35. Reddy KB, Mangold GL, Tandon AK, et al: Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res 52: 3636-3641, 1992.
36. Wells A, Ware MF, Allen FD and Lauffenburger DA: Shaping up for shipping out: PLCgamma signaling of morphology changes in EGF stimulated fibroblast migration. Cell Motil Cytoskeleton 44: 227-233, 1999.
37. Kanekura T, Chen X and Kanzaki T: Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 99: 520-528, 2002.
38. Zhang YG, Du J, Tian XX, Zhong YF and Fang WG: Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas. Chin Med J 120: 1597-1605, 2007.
39. Ellerbroek SM, Halbleib JM, Benavidez M, et al: Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 61: 1855-1861, 2001.
40. Menashi S, Serova M, Ma L, Vignot S, Mourah S and Calvo, F: Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial, cells. Cancer Res 63: 7575-7580, 2003.
41. Reddy KB, Krueger JS, Kondapaka SB and Diglio CA: Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int J Cancer 82: 268-273, 1999.